FAM171B

Across TCGA pan-cancer cohorts, FAM171B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM171B data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM171B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM171B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUSC, and COAD are the cancer types where FAM171B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.623	.005	36	view →
LUSC	OS	Median	II,III,IV	0.207	0.641	<.001	36	view →
COAD	OS	Median	II,III,IV	0.054	0.860	<.001	24	view →
ACC	DFS	Median	All	0.195	0.748	.003	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM171B–UCEC (DFS)

Open the UCEC breakdown →